Skip to main content

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 '22

By: Newsfile
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Dallas, Texas--(Newsfile Corp. - December 19, 2022) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH). The full report can be accessed by clicking on the following link: https://stonegateinc.com/reports/BPTH_Q322.pdf

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Strong IP Position
  • Ongoing Clinical Trials
  • First Patients Recently Dosed

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/148698_figure1_550.jpg

Click image above to view full announcement.


About Stonegate Capital Partners
Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high-quality investment opportunities.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/148698

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  247.58
-6.21 (-2.45%)
AAPL  308.43
-2.80 (-0.90%)
AMD  467.47
-55.73 (-10.65%)
BAC  53.73
-0.16 (-0.30%)
GOOG  362.96
-6.31 (-1.71%)
META  590.36
-37.21 (-5.93%)
MSFT  415.88
-12.17 (-2.84%)
NVDA  205.00
-13.66 (-6.24%)
ORCL  210.85
-25.49 (-10.79%)
TSLA  389.42
-29.03 (-6.94%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.